EVIDENCE LIBRARY
An adenosine-linked pyrrolobenzodiazepine lost expected DNA binding
A negative laboratory result showed how a substituent could disrupt the anticipated activity of a DNA-binding scaffold.
A negative laboratory result showed how a substituent could disrupt the anticipated activity of a DNA-binding scaffold.
The unexpected finding
The investigators linked an adenosine nucleoside to the C8 position of a pyrrolobenzodiazepine through a linker. The conjugate did not show the expected cytotoxicity in tested murine cells or activity against the tested mycobacterial strains. DNase footprinting also did not show binding to the examined guanine-containing DNA sequences.
Molecular dynamics suggested that the adenosine group impaired accommodation in the DNA minor groove and prevented the expected covalent interaction.
Negative findings constrain structural assumptions
The simulations offered an explanation, while the experimental assays supplied the direct observations. Neither establishes how every related conjugate behaves. A compound based on a known active scaffold can lose activity after modification, so scaffold ancestry alone is insufficient.
This study is not about the effects of clinical sedative benzodiazepines. Its forensic relevance is to chemical interpretation: retain the entire identified structure and measured function before attributing biological properties. The negative result is scientifically informative rather than a failed basis for claiming a new therapy.
Source paper
Original analysis of the supplied journal article, identified as PMC7179398.